CN102399718B - Secondary Lactobacillus casei strain GMNL 133, composition for improving Atopic dermatitis or other anaphylactic diseases and application thereof - Google Patents
Secondary Lactobacillus casei strain GMNL 133, composition for improving Atopic dermatitis or other anaphylactic diseases and application thereof Download PDFInfo
- Publication number
- CN102399718B CN102399718B CN201110319407.7A CN201110319407A CN102399718B CN 102399718 B CN102399718 B CN 102399718B CN 201110319407 A CN201110319407 A CN 201110319407A CN 102399718 B CN102399718 B CN 102399718B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus
- lactobacillus casei
- gmnl
- casei strain
- strain gmnl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to the separated secondary Lactobacillus casei strain GMNL 133 of one kind, China typical culture collection center (CCTCC) is preserved in, deposit number is CCTCC No.M2011311.The secondary Lactobacillus casei strain GMNL 133 can be used to manufacture treatment Atopic dermatitis or the composition of other anaphylactic diseases.Additionally, the present invention relates to a kind of composition including the secondary Lactobacillus casei strain GMNL 133, and the content of secondary Lactobacillus casei strain GMNL 133 can effectively treat Atopic dermatitis or other anaphylactic diseases.
Description
Technical field
The present invention relates to a kind of lactobacillus strains and application thereof, more particularly to a kind of secondary Lactobacillus casei strain and including
Its composition and purposes for improving anaphylactic disease.
Background technology
Allergy is a kind of acquired adverse reaction produced to normal innocuous substance on immune.What allergic reaction caused
Symptom has itch, cough, asthma, sneeze, tearful eyes, inflammation and tired etc..It is believed that allergic reaction is exempted from including early stage selectivity
Epidemic disease is reacted and late phase inflammation reaction.It has been reported that anaphylactogen (such as pollen and dust mite) is by stimulating high affinity immune globulin E
(IgE) allergic reaction of intermediary's early stage.Specifically, when mast cell and basophilic granulocyte are subject to allergy primary stimuli, meeting
Release histamine and cytohormone.Cytohormone is then by assembling the allergic reaction in inflammatory cells intermediary late period.Also there is report
Point out eosinophil, macrophage, lymphocyte, neutrophil cell and the hematoblastic inflammation for collecting unlatching Advanced Malignant
Disease reaction cycle.The allergic reaction in late period strengthens initial immune response, then promotes to discharge more inflammatory cells.
There is now various therapies for treating allergic symptom, comprising use anti-allergic agent and histamine H- receptor antagonists
(antihistaminicum).Antihistaminicum can mitigate the symptoms such as the congested, itch and the swelling that act on that destination organization causes by histamine, and
And can prevent or relax many symptoms caused by mast cell degranulation.But, while also there is report, it is indicated that antihistaminicum meeting
Produce some side effects, for example alertness reduction, slow in reacting and drowsiness.
Atopic dermatitis is a kind of most common allergy of children.It is part to treat the conventional method of Atopic dermatitis
Steroid treatment, but atopic skin disease shape is difficult to eradicate in fact, and through often recurrence after drug withdrawal.Furthermore, long-term use class is consolidated
Alcohol therapy easily produces side effect, such as atrophoderma is thinning, change o f skin colour, become mildewed, acne long etc..Therefore, few side effects
And it is safe, patient and clinically desired can be turned into medicament safe to use.
Probiotics helps health by medical field and scientific circles' identification in recent years, and has no side effect.The United Nations's grain agriculture
Be defined as probiotics (probiotics) by industry tissue (FAO) and the World Health Organization (WHO)：Microorganism living, when it is in
When right quantity is administered, the health benefits of host one (health benefit) can be assigned.What can be used as probiotics at present is micro-
Biology has numerous species, such as Lactobacillus (Lactobacillus), double fork lever Pseudomonas (Bifidobacterium), milk-globule
Pseudomonas (Lactococcus), enterococcus spp (Enterococcus), Blastocystis (yeasts), streptococcus
(Streptococcus) etc..
Lactobacillus is the gram-positive facultative anaerobic bacteria of a group, is prevalent in the intestines and stomach and vagina of the mankind
It is interior, being capable of fermenting carbohydrate and with lactic acid as main metabolites.The research and clinical test for having many all confirm lactic acid successively
Important correlation is there are between bacillus and health.At present, Bacillus acidi lactici is it has been found that effect includes：(1) enteron aisle is promoted
The bacterium of micropopulation is balanced each other；(2) pre- anti-diarrhea；(3) danger of colon cancer is reduced；(4) stimulating gastrointestinal epithelium mucosal system
Normal development and function；(5) various vitamins and nutrient are produced；And (6) prevention and treatment vaginitis.
The content of the invention
It is an aspect of the invention to provide a kind of separated secondary Lactobacillus casei strain GMNL-133, during it is preserved in
State's Type Tissue Collection (China Center for Type Culture Collection, CCTCC), deposit number
It is CCTCC No.M2011311.
It is another aspect of the invention to provide a kind of purposes of secondary Lactobacillus casei strain GMNL-133, it is used to manufacture
Treat the composition of Atopic dermatitis.
Above-mentioned aspect of the invention, proposes a kind of composition for treating Atopic dermatitis, including secondary cheese
Lactobacillus strains GMNL-133, and the content of the secondary Lactobacillus casei strain GMNL-133 can be effectively improved Atopic dermatitis.
Another aspect of the present invention is to provide a kind of purposes of secondary Lactobacillus casei strain GMNL-133, and it is used to manufacture
Treat the composition of anaphylactic disease.
Above-mentioned aspect of the invention, proposes a kind of composition for treating anaphylactic disease, including secondary cheese lactic acid
Bacillus strain GMNL-133, and the content of secondary Lactobacillus casei strain GMNL-133 can be effectively improved anaphylactic disease.
According to one embodiment of the invention, secondary Lactobacillus casei strain GMNL-133 can be viable bacteria or through the dead of Overheating Treatment
Bacterium.And the composition for treating Atopic dermatitis or anaphylactic disease can be medical composition or food compositions.
According to another embodiment of the present invention, the composition for the treatment of Atopic dermatitis or anaphylactic disease can further include to
Few other bacterial strains of one kind, other bacterial strains are selected from by lactobacillus acidophilus (Lactobacillus acidophilus), plant
Thing Bacillus acidi lactici (Lactobacillus plantarum), bifidobacterium longum (Bifidobacterium longum), acidified milk
It is acidfast bacilli (Lactobacillus fermentum), Bulgarian Lactobacillus (Lactobacillus bulgaricus), thermophilic
Hot streptococcus (Streptococcus thermophilus), milk Lactobacillus casei (Lactobacillus cremors), sandlwood
Saccharolactic acid bacillus (Lactobacillus rhamnosus), lactobacillus reuteri (Lactobacillus reuteri) and on
State the group that any combination of bacterium is constituted.
Brief Description Of Drawings
Fig. 1 is separation strains GMNL-133 in the aspect graph under microscope.
Fig. 2 is the RAPD electricity of secondary Lactobacillus casei strain GMNL-133 and secondary Lactobacillus casei strain in other commercially available prod
Swimming figure.
Fig. 3 is that secondary Lactobacillus casei strain GMNL-133 stimulates respectively with secondary Lactobacillus casei strain in other commercially available prod
The column diagram of the IFN-γ expression quantity that Mouse spleen cells are produced.
Fig. 4 A to 4B are respectively in sensitized mice model experiment, and IgE and IgG2a expression quantity are with placebo in the serum of each group
The standardized column diagram of expression quantity of group, * marks represent significant difference (the p ＜ having compared with placebo statistically
0.05)。
Fig. 5 A to 5D are respectively in sensitized mice model experiment, TGF-β, IFN- in the spleen cell nutrient solution of each group
γ, IL-10 and IL-17 expression quantity are represented and placebo with the standardized column diagram of the expression quantity of placebo, * marks
Compared to significant difference (p ＜ 0.05) statistically.
Fig. 6 A are the column diagram of each group mouse right ear thickness results during Atopic dermatitis mouse model is tested, * marks
Represent the significant difference (p ＜ 0.05) having compared with placebo statistically.
Fig. 6 B to 6C are respectively in the experiment of Atopic dermatitis mouse model, IgE and IgG1 in each group mice serum
With the standardized column diagram of the expression quantity of placebo, * marks are represented compared with placebo to be had statistically expression quantity
Significant difference (p ＜ 0.05).
During Fig. 6 D are the experiment of Atopic dermatitis mouse model, the expression quantity of the TNF-α in each group mouse ear tissue with
The standardized column diagram of expression quantity of placebo, * marks represent the significant difference having compared with placebo statistically
(p ＜ 0.05).
Specific embodiment
There is report to point out that by adjusting cytohormone allergy can be treated at present.Wherein, gamma interferon (IFN-γ) can suppress
The overexpression of the cytohormone of II types helper cell (Th2), particularly suppresses the secretion of -4 (IL-4) of the white element of Jie, and then drops
The propagation of low bone-marrow-derived lymphocyte.Additionally, IFN-γ can also stimulate the immune response of I types helper cell (Th1), suppress the conjunction of IgE
Into.It is therefore believed that IFN-γ is effective for treatment allergy.
Therefore, the present invention provides the lactobacillus paracasei strain GMNL-133 of a novelty, and the bacterial strain GMNL-133 tools stimulate
The ability of the spleen cell secretion of gamma-IFN of mouse, can be used to manufacture the composition for the treatment of anaphylactic disease.Lactobacillus paracasei strain
GMNL-133 was preserved in China typical culture collection center on 26th according to the regulation of budapest treaty in September in 2011
(CCTCC) (China, Wuhan, Wuhan University, 430072), preserving number is CCTCC No.M2011311.This lactobacillus paracasei strain
GMNL-133 (CCTCC No.M2011311) can comprising at least one pharmaceutically acceptable excipient and/or diluent etc. its
Its composition, such as glucose, maltodextrin, baby milk, FOS, magnesium stearate, yogurt spices, other be difficult to separate into
Divide or above-mentioned any combination, and this other composition and compound method are ripe for technical field those of skill in the art
Know.In addition, the consumption of lactobacillus paracasei strain GMNL-133 (CCTCCNo.M2011311) can be every kilogram about 1 × 106To about 1
×1011Individual CFU (CFU/g).
So-called " anaphylactic disease " refer to Atopic dermatitis, allergic rhinitis and asthma and some specific foods with
The allergy that insect bites cause.These diseases can cause considerable degree of inflammatory response, cause skin, mucous membrane tissue or blood vessel
Chronic inflammation.
According to one embodiment of the invention, the composition for treating anaphylactic disease includes lactobacillus paracasei strain GMNL-133, and
The content of secondary Lactobacillus casei strain GMNL-133 can be effectively improved anaphylactic disease.
Above-mentioned secondary Lactobacillus casei strain GMNL-133 can be viable bacteria or the dead bacterium through Overheating Treatment.Treatment anaphylactic disease
Composition can be Orally administered composition, such as medical composition or food compositions.
According to another embodiment of the present invention, the composition for treating anaphylactic disease can further include at least one other bacterium
Strain.Other bacterial strains are selected from by lactobacillus acidophilus (Lactobacillus acidophilus), lactobacillus plantarum
(Lactobacillus plantarum), bifidobacterium longum (Bifidobacterium longum), fermentation lactobacillus
(Lactobacillus fermentum), Bulgarian Lactobacillus (Lactobacillus bulgaricus), thermophilus
Bacterium (Streptococcus thermophilus), milk Lactobacillus casei (Lactobacillus cremors), sandlwood saccharolactic acid
Bacillus (Lactobacillus rhamnosus), lactobacillus reuteri (Lactobacillus reuteri) and above-mentioned appoint
The constituted group of meaning combination.In general, the bacterium amount of other bacterial strains can be about 1 × 107CFU/g or more.
Separation, screening and the identification of embodiment 1, bacterial strain
The present inventor separates over one hundred plant of Bacillus acidi lactici from a healthy human body intestines and stomach corpse or other object for laboratory examination and chemical testing, and sets up a separation strains strain library.
There is the Bacillus acidi lactici for slowing down treatment allergy-related disorder potentiality to find, respectively by each Bacillus acidi lactici in strain library and mouse
Spleen cell is co-cultured, and carries out the analysis of Mouse spleen cells IFN-γ secretion amount, and then therefrom filter out separation strains GMNL-
133 is a Bacillus acidi lactici that can stimulate the Mouse spleen cells a large amount of IFN-γs of secretion.
This separation strains GMNL-133 is carried out into every strain idenfication analysis.Fig. 1 is separation strains GMNL-133 under microscope
Aspect graph.Separation strains GMNL-133 Preliminary experiment results are shown as Gram-positive bacillus, do not have catalase, oxidizing ferment and motion
Property, can all be grown under aerobic and anaerobic environment.
Further analyzed with 16S rDNA sequences and API 50CHL identification systems.The 16S of separation strains GMNL-133
RDNA partial sequences such as SEQ ID No：Shown in 1.Table one is the knot that separation strains GMNL-133 is analyzed with API50CHL identification systems
Really.
The analysis result of the API 50CHL identification systems of the separation strains GMNL-133 of table one
-：Negative reaction；+：Positive reaction；W：Faint positive reaction
Summary qualification result shows that separation strains GMNL-133 is secondary Lactobacillus casei.
The difference of the secondary Lactobacillus casei of embodiment 2, secondary Lactobacillus casei strain GMNL-133 and other commercially available prod
Analysis
Secondary Lactobacillus casei strain GMNL-133 (is for example unified LP33 Yoghourts, include secondary cheese lactic acid with commercially available yoghourt
Bacillus strain LP33), yogurt (such as the vigour yogurt of Japanese kylin company adult includes secondary Lactobacillus casei strain KW3110),
Probiotic health food (such as hundred bright raw quick probiotics of skill prestige include secondary Lactobacillus casei strain BRAP-01) etc. is containing secondary dry
Bacterial strain in the product of Lactobacillus casei carries out variance analysis, comprising randomly amplified polymorphic DNA (RAPD) electrophoretic analysis and API
50CHL identification systems are analyzed.
RAPD electrophoretic analysis is 5 '-CCGCGACGTT-3 ' (SEQ ID No using sequence：2) primer carries out polymerase chain
Formula is reacted, many to analyze the secondary Lactobacillus casei strain random amplification in secondary Lactobacillus casei strain GMNL-133 and commercially available prod
Difference between state property DNA.PCR condition is 93 DEG C, 10 minutes, double-stranded DNA denaturation is separated into single-stranded.Then
Carry out following circulation 35 times：93 DEG C, 1 minute；36 DEG C, 1 minute；74 DEG C, 1 minute.It is last to carry out 5 minutes with 74 DEG C to expand
DNA fragmentation.DNA electrophoretic analysis is carried out with 1.5% agarose after the completion of reaction.
Fig. 2 is the RAPD electricity of secondary Lactobacillus casei strain GMNL-133 and secondary Lactobacillus casei strain in other commercially available prod
Swimming figure.Wherein swimming lane M is molecular weight markers, and swimming lane 1 to 4 is respectively the RAPD of LP33, KW3110, GMNL-133 and BRAP-01
Collection of illustrative plates.From Fig. 2 results, GMNL-133 is all different from the RAPD collection of illustrative plates of KW3110, LP33, BRAP-01.
Secondary bar Lactobacillus casei strain GMNL-133 reflects with the API 50CHL of the secondary Lactobacillus casei strain of other commercially available prod
Determine the result of network analysis as shown in Table 2.
The secondary bar Lactobacillus casei of table two strain GMNL-133 reflects with the API of the secondary Lactobacillus casei strain of other commercially available prod
Determine the result of network analysis
-：Negative reaction；+：Positive reaction；W：Faint positive reaction
The biochemical reaction of secondary Lactobacillus casei strain GMNL-133, LP33 and BRAP-01 is all differed as shown in Table 2.Its
In, secondary Lactobacillus casei strain GMNL-133 and LP33 is to L- sorboses, methyl-α D-Glucoses glycosides, amarogentin and D- containing pine
The biochemical reaction of trisaccharide is entirely different.And secondary Lactobacillus casei strain GMNL-133 and BRAP-01 is then for L-arabinose, D-
Ribose, methyl-D- xylosides, L- rhamnoses, inositol, D- D-sorbites, D- lactose, D- melibioses, synanthrin, D- containing melezitose,
The biochemical reaction of D- turanoses, D- lyxoses, D-Tag and gluconic acid is entirely different.
Understand in sum secondary Lactobacillus casei strain GMNL-133, KW3110, LP33 and BRAP-01 gene order with
And biochemical reaction is all differed, four plants of secondary Lactobacillus casei strains are different bacterial strains really, it was demonstrated that secondary cheese breast of the invention
Acidfast bacilli strain GMNL-133 is a novel strain.
Embodiment 3, secondary Lactobacillus casei strain GMNL-133 and other secondary Lactobacillus casei strains are in stimulation mouse spleen
Cell produces the secretory volume of IFN-γ to compare
Respectively with the secondary Lactobacillus casei strain in the strain of secondary Lactobacillus casei GMNL-133 and foregoing various commercially available prod,
After KW3110, LP33 and BRAP-01, with the spleen cell co-incubation of normal mouse, compare the IFN-γ of Mouse spleen cells
Secretory volume.
With containing 10% hyclone the culture mediums of RPMI 1640 (Gaithersburg, MD,
USA the spleen cell of BALB/c mouse is taken from) culture.By 4x105Individual Mouse spleen cells are added in 96 orifice plates, and are added respectively
Enter 106Above-mentioned each lactic acid bacillus mycopremna, in 37 DEG C, containing culture 48 hours in the environment of 5% carbon dioxide.Afterwards, cell is trained
Supernatant is supported with commercial ELISA Assay kit (OptEIA Mouse IFN-γs Set, BD Biosciences
San Diego, CA, USA) determine IFN-γ content therein.
Fig. 3 is that secondary Lactobacillus casei strain GMNL-133 stimulates respectively with secondary Lactobacillus casei strain in other commercially available prod
The IFN-γ secretion amount that Mouse spleen cells are produced.From Fig. 3 results, secondary Lactobacillus casei strain GMNL-133 can stimulate greatly
Amount IFN-γ secretion is produced, and secretory volume is about at least more than 3 times of the lactobacillus paracasei strain in other commercially available prod, display
Secondary Lactobacillus casei strain GMNL-133 of the invention has compared with other lactobacillus paracasei strains for treatment allergy preferably imitates
Really.
The influence of embodiment 4, secondary Lactobacillus casei strain GMNL-133 for the cytohormone secretion of sensitized mice
The mouse of sensitized mice pattern is purchased from the female BAl BIc/c mouse of Taiwan Le Sike biotechnologies.Raise in control
The Animal House of light and temperature.After BALB/c mouse is entered the room one week, experiment is started after animal is stable.
Mouse is divided into normal group, experimental group and placebo to be tested.Experimental group exists respectively with placebo mouse
Experiment starts the 0th day i.e. using the ovalbumin (ovalbumin, OVA) and the aluminium glue adjuvant of 4mg of the μ g of intraperitoneal injection 50
(aluminum hydroxide adjuvant, alum) in Mice Body, and when testing the 14th and 28 day, then with 25 μ g's
The alum duplicate injection mouse of OVA and 4mg.
During carrying out in experiment, 0.5 milliliter of RO water of i.e. daily feeding normal group and placebo mouse since the 1st day,
And experimental mice then feeding 2x107Lactobacillus paracasei strain GMNL-133 viable bacterias.Experiment is carried out 35 days altogether, will in the 35th day
Sacrifice, and taken a blood sample by mousetail before putting to death, isolate serum and analyzed for the follow-up IgE and IgG2a that carries out.
By each group BALB/c mouse with CO2At smother play after death, spleen is taken out with aseptic technique and is placed in microorganism
With culture dish, 6ml PBS are added, spleen extruding is milled to by suspension with glass bar.Draw suspension and be slowly added to thing
First installed 6ml Ficoll-Hypaque (17-1400-02, Pharmacia) 15ml centrifuge tubes, carry out gradient centrifugation with
Spleen cell is separated into (720g, 20min), sediment is red blood cell.Spleen cell is taken out from interface, with PBS two
After secondary, cell concentration is adjusted to 4 × 10 with RPMI-1640 culture mediums6Cell/ml, spleen cell is noted with each hole 100 μ l
In entering 96 orifice plates.
Spleen cell takes supernatant in addition OVA (culture concentration 30 μ g/mL) culture after 48 hours, is detectd with ELISA modes
Survey TGF-β, IFN-γ, the concentration of IL-10 and IL-17.
Fig. 4 A to 4B are respectively in sensitized mice model experiment, and IgE and IgG2a expression quantity are with placebo in the serum of each group
The standardized column diagram of expression quantity of group, * marks represent significant difference (the p ＜ having compared with placebo statistically
0.05).From Fig. 4 A to 4B results, in the BALB/c mouse serum of experimental group (feeding lactobacillus paracasei strain GMNL-133)
OVA specific IgEs, significant decline has been compared with placebo.However, experimental group (feeding lactobacillus paracasei strain GMNL-
133) OVA specific IgG 2a, compare with placebo in BALB/c mouse serum, are significant increases.Referred to according to document
Go out, IgG2a antibody is as secreted by Th1 cells.Therefore, feeding pair Lactobacillus casei strain GMNL-133 may be such that BALB/c is small
The Th1 cell activations of mouse, and then reduce the generation of OVA specific IgEs in serum.
Fig. 5 A to 5D are then respectively in sensitized mice model experiment, TGF-β, IFN- in the spleen cell nutrient solution of each group
γ, IL-10 and IL-17 expression quantity are represented and comfort with the standardized column diagram of the expression quantity of placebo, wherein * marks
Agent group is compared to the significant difference (p ＜ 0.05) having statistically.From Fig. 5 A to 5D results, feeding lactobacillus paracasei strain
Experimental group after GMNL-133 is compared with placebo, TGF-β, IFN-γ, IL-10 in the spleen cell nutrient solution of experimental group
And IL-17 concentration has significant increase.
Many anaphylactias are because the immune response between Th1 cells and Th2 cells is uneven, and to anaphylactogen
Caused by the reaction relatively immune response of deflection Th2 cells.And there is document to point out, and by improving the balance of Th1/Th2 immune systems, will
Th2 cell effects turn to Th1 immune responses, can slow down anaphylactic disease.When the immunization route of Th1 cells is partial in immune response,
Th1 cells meeting secretion of gamma-IFN, helps generation, activated macrophage, natural killer cell and the poisoning type T of IgG2a antibody thin
Born of the same parents, strengthen cell immune response.Additionally, Th17 cells can secrete IL-17, can be as between congenital immunity and acquired immunity
The bridge of regulation, that is to say, that Th17 cells are to be located at the hub site adjusted between cellular immunity and humoral immunity.
Furthermore, another group of adjustment type T cells can be reached by suppressing the immune response of Th2 cells and suppress anaphylactic disease
Occur.Adjustment type T cell is characterized in that can secrete IL-10 or TGF-β, and then suppresses activation and the hyperplasia of target cell.
In sum, secondary Lactobacillus casei strain GMNL-133 of the invention can stimulate the Th-17 of vivo immuning system
Cell, and then cause that the immune response of Th1/Th2 transfers Th1 approach to.Furthermore, secondary Lactobacillus casei strain GMNL- of the invention
133 can also stimulate adjustment type T cell, and then suppress the immune response of Th2 cells, reach and slow down allergic reaction.
The improvement effect assessment of embodiment 5, secondary Lactobacillus casei strain GMNL-133 for tool Atopic dermatitis mouse
To be raised in control light and temperature purchased from 6 weeks big normal male BALB/c mouses of Taiwan Le Sike biotechnologies
The Animal House of degree.After BALB/c mouse is entered the room one week, experiment is started after animal is stable.
Mouse is divided into normal group, experimental group and placebo to be tested.Experimental group exists respectively with placebo mouse
Experiment start the 0th day when, by 10 microlitres of 0.3% 3 nitre chlorobenzene solution coat BALB/c mouse auris dextra inner side, after reality
Test during carrying out, be coated with three nitre chlorobenzene solutions of same dose in same area three-times-weekly, atopy is produced to induce mouse
Dermatitis, forms Atopic dermatitis mouse model.Meanwhile, during carrying out in experiment, i.e. daily feeding was normal since the 1st day
0.5 milliliter of RO water of group and placebo mouse, and experimental mice then feeding 2x107Lactobacillus paracasei strain GMNL-133 live
Bacterium.
Experiment is carried out 21 days altogether.In the 22nd day by sacrifice, and before putting to death with finger gauge measure mouse right ear thickness,
Gather mouse ear tissue and taken a blood sample by mousetail, isolate serum for carrying out immunoglobulin analysis in the future.Mouse ear
Tissue is placed in the 50mM phosphate buffer solutions containing protease inhibitors, after being homogenized, 30 is centrifuged with 18870g gravity
Minute, supernatant is taken with the content of tumor necrosis factor TNF-alpha in enzymoimmunoassay measurement supernatant.
Fig. 6 A figures are the column diagram of each group mouse right ear thickness results during Atopic dermatitis mouse model is tested.Fig. 6 B
It is respectively in the experiment of Atopic dermatitis mouse model to 6C, IgE and IgG1 expression quantity in each group mice serum is comforting
The standardized column diagram of expression quantity of agent group.Fig. 6 D figures are each group mouse ear group during Atopic dermatitis mouse model is tested
The expression quantity of the TNF-α in knitting is with the standardized column diagram of the expression quantity of placebo.The result representation of Fig. 6 B to Fig. 6 D
Be that content measured by placebo is 100%, normal group and the content measured by experimental group respectively with placebo ratio
Compared with * marks represent the significant difference (p ＜ 0.05) having compared with placebo statistically.
According to the result of Fig. 6 A to 6D, it is displayed under Atopic dermatitis mouse model, feeding lactobacillus paracasei strain
The TNF-α secretion amount of IgE, IgG1 and otic tissues in the mouse of GMNL-133 viable bacterias (experimental group) its ear thickness, serum, with
The mouse of non-feeding lactobacillus paracasei strain GMNL-133 viable bacterias (placebo) is compared, and is all decreased significantly.Therefore, the present invention
Lactobacillus paracasei strain GMNL-133 bacterial strains can obviously improve the symptom of Atopic dermatitis, it is anti-for allergy in organism
Should be also inhibited.
Claims (2)
1. a kind of separated secondary Lactobacillus casei strain GMNL-133 is preparing the medical composition for the treatment of Atopic dermatitis
In application, wherein secondary Lactobacillus casei strain GMNL-133 is preserved in China typical culture collection center (CCTCC), protects
It is CCTCC No.M2011311 to hide numbering.
2. separated secondary Lactobacillus casei strain GMNL-133 according to claim 1 is preparing treatment atopic skin
Application in scorching medical composition, wherein the medical composition is further included：
At least one other bacterial strains, other bacterial strains are selected from by lactobacillus acidophilus (Lactobacillus
Acidophilus), lactobacillus plantarum (Lactobacillus plantarum), bifidobacterium longum (Bifidobacterium
Longum), fermentation lactobacillus (Lactobacillus fermentum), Bulgarian Lactobacillus (Lactobacillus
Bulgaricus), streptococcus thermophilus (Streptococcus thermophilus), milk Lactobacillus casei (Lactobacillus
Cremors), rhamnose lactic acid bacteria (Lactobacillus rhamnosus), lactobacillus reuteri (Lactobacillus
) and the group that is constituted of above-mentioned any combination reuteri.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110319407.7A CN102399718B (en) | 2011-10-14 | 2011-10-14 | Secondary Lactobacillus casei strain GMNL 133, composition for improving Atopic dermatitis or other anaphylactic diseases and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110319407.7A CN102399718B (en) | 2011-10-14 | 2011-10-14 | Secondary Lactobacillus casei strain GMNL 133, composition for improving Atopic dermatitis or other anaphylactic diseases and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102399718A CN102399718A (en) | 2012-04-04 |
| CN102399718B true CN102399718B (en) | 2017-07-07 |
Family
ID=45882373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110319407.7A Active CN102399718B (en) | 2011-10-14 | 2011-10-14 | Secondary Lactobacillus casei strain GMNL 133, composition for improving Atopic dermatitis or other anaphylactic diseases and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102399718B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI592487B (en) * | 2016-10-05 | 2017-07-21 | 益福生醫股份有限公司 | Novel lactobacillus paracasei subsp. paracasei k56 |
| CN107114794A (en) * | 2017-06-06 | 2017-09-01 | 上海真合生物技术有限公司 | Probiotic composition for strengthening antiallergy ability |
| TWI731209B (en) * | 2018-01-09 | 2021-06-21 | 柯順議 | Probiotics composition and uses thereof |
| CN110151672B (en) * | 2018-02-12 | 2022-04-05 | 景岳生物科技股份有限公司 | Application of lactobacillus plantarum GMNL-6 composition in skin care |
| CN108707557B (en) * | 2018-03-23 | 2021-04-16 | 景岳生物科技股份有限公司 | Probiotic composition for preventing, improving or slowing pancreatic cancer and application thereof |
| TWI746955B (en) * | 2018-04-25 | 2021-11-21 | 日商曾根農場股份有限公司 | Composition for Type I Allergy |
| WO2020084589A1 (en) * | 2018-10-26 | 2020-04-30 | Sofar S.P.A. | Bacterial strains of the lactobacillus paracasei species for use, oral or topical, in the treatment of disorders of the female urogenital tract |
| CN110892914A (en) * | 2019-11-20 | 2020-03-20 | 内蒙古伊利实业集团股份有限公司 | New application of lactobacillus paracasei K56 in improvement of asthma and related allergic symptoms |
| CN112940968B (en) * | 2021-02-07 | 2022-07-01 | 山东凤凰生物科技股份有限公司 | Lactobacillus fermentum, lactobacillus fermentum culture and preparation method thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0755908B2 (en) * | 1992-11-24 | 1995-06-14 | 財団法人京都パストゥール研究所 | Immune function promoter |
| CN1316030C (en) * | 2002-11-06 | 2007-05-16 | 景岳生物科技股份有限公司 | New usage of strain of lactobacillus for curing irritability |
| TWI284149B (en) * | 2004-03-25 | 2007-07-21 | Genmont Biotech Inc | Novel microorganism strain GMNL-32 of lactobacillus paracasei and its use for treating allergy related diseases |
| CN101575582B (en) * | 2008-05-08 | 2011-10-12 | 景岳生物科技股份有限公司 | Lactobacillus separation strains with anti-inflammatory activity and application thereof |
-
2011
- 2011-10-14 CN CN201110319407.7A patent/CN102399718B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102399718A (en) | 2012-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102399718B (en) | Secondary Lactobacillus casei strain GMNL 133, composition for improving Atopic dermatitis or other anaphylactic diseases and application thereof | |
| CN114032193B (en) | Lactobacillus paracasei 207-27 and application thereof | |
| CN102115721B (en) | Lactobacillus isolated strains with anti-inflammatory activity and use thereof | |
| CN105579574B (en) | Novel lactic acid bacteria and medicine, diet product and feed containing novel lactic acid bacteria | |
| CN101575582B (en) | Lactobacillus separation strains with anti-inflammatory activity and application thereof | |
| CN114317320B (en) | Bifidobacterium breve 207-1 and application thereof | |
| Hong et al. | Effects of kefir supernatant and lactic acid bacteria isolated from kefir grain on cytokine production by macrophage | |
| CN108367031A (en) | Thermophilic mucin Ackermam Salmonella is used to treat the purposes of inflammatory condition | |
| KR101504373B1 (en) | Lactobacillus paracasei strain lt12 as immunity regulatory agent | |
| TW200944215A (en) | Lactobacillus isolates having anti-inflammatory activities and uses of the same | |
| CN107574131A (en) | Probiotic bifidobacterium strains | |
| EP2581461B1 (en) | Composition and use of lactobacillus paracasei strain GMNL-133 in treating atopic dermatitis or other allergic diseases | |
| CN101328468B (en) | Antiallergic lactic acid bacteria | |
| US11667977B2 (en) | Method of using a medication or a food supplement with lactobacillus strains isolated from kimere for strengthining the immune system | |
| Mei et al. | Immunomodulatory Activity of Lactococcus lactis A17 from Taiwan Fermented Cabbage in OVA‐Sensitized BALB/c Mice | |
| TWI398259B (en) | Composition and use of lactobacillus paracasei strain gmnl-133 in treating atopic dermatitis or other allergic diseases | |
| CN107114794A (en) | Probiotic composition for strengthening antiallergy ability | |
| CN103550258B (en) | The purposes of lactobacillus strain immunity moderation reaction | |
| CN106262931A (en) | Lactobacillus plantarum application in preparation antiallergic product | |
| JP7358001B2 (en) | Lactic acid bacteria, interleukin-22 production inducer, skin barrier function enhancer | |
| KR20130049554A (en) | Composition for preventing or treating atopic dermatitis | |
| CN110087656A (en) | Application of the inosine in treatment T-reg lacks | |
| CN102028224B (en) | Antiallergic lactobacillus | |
| US8753624B2 (en) | Composition and use of Lactobacillus paracasei strain GMNL-133 in treating atopic dermatitis or other allergic diseases | |
| TW201106957A (en) | The new strain of Lactobacillus plantarum LP28 and its use in treating allergy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |